DRUG
Romosozumab
romosozumab 210 milligrams monthly
Status
Recruiting
Phase
Phase 4
Enrollment
50
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.
Interventions
Treatment arms and agents.
DRUG
Teriparatide
teriparatide 20 micrograms daily
Timeline
From registration to results.
First posted
Aug 16, 2024
Study start
Feb 3, 2025
Primary completion
Dec 30, 2027
Study completion
Apr 1, 2028
Results posted
Not reported
Registry updated
Apr 17, 2026
Outcomes
What the study measures.
Primary outcomes
Lumbar spine areal bone mineral density
Time frame · Month 0 to 12
Change in lumbar spine bone density between month 0 and month 12
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 45 Years
- Maximum age
- Not reported
- Sex
- FEMALE
- Healthy volunteers
- Yes
Inclusion Criteria: * women aged 45+ * postmenopausal * osteoporotic with high risk of fracture Exclusion Criteria: * no significant previous use of bone health modifying treatments * known congenital or acquired bone disease other than osteoporosis * significant renal disease, liver disease, cardiopulmonary disease, or psychiatric disease * abnormal calcium or parathyroid hormone level * serum vitamin D \<20 ng/dL * anemia (hematocrit \<32%) * history of malignancy (except non-melanoma skin carcinoma) * excessive alcohol use or substance abuse * known contraindications to romosozumab or teriparatide
Study locations
1 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
Massachusetts General Hospital
Boston, Massachusetts, United States
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Teriparatide.
NCT IDStudyPhase / statusEnrollmentUpdated
Sequential Therapies After Osteoanabolic Treatment
424 General Military Hospital · Osteoporosis, Postmenopausal
Not applicable
Recruiting
150
2026-07
A Study of B-3E07 and Forsteo® in Healthy Adult Female Participants
Syneos Health · Healthy Volunteers
Phase 1
Recruiting
48
2026-07
Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid
University of Edinburgh · Osteogenesis Imperfecta
Phase 4
Completed
350
2026-06
Teriparatide (Forsteo) Treatment in Postmenopausal Women: Mechanism of Action
Sheffield Teaching Hospitals NHS Foundation Trust · Osteoporosis
Phase 4
Completed
19
2026-05
Preoperative Teriparatide Use on Insertional Torque of Pedicle Screws for Lumbar Fusion Surgery
The University of Hong Kong · Osteoporosis · Fusion of Spine, Lumbar Region
Not applicable
Active, not recruiting
192
2026-05
Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover
Madhumathi Rao · Age-Related Osteoporosis
Phase 4
Active, not recruiting
60
2026-05
A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens
Shenzhen Salubris Pharmaceuticals Co., Ltd. · Postmenopausal Women With Osteoporosis
Phase 2
Recruiting
200
2026-05
Effects of Teriparatide (PTH) on Bone in Men and Women With Osteoporosis
University Health Network, Toronto · Osteoporosis
Not applicable
Active, not recruiting
100
2026-05
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.